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CLINICAL REVIEW 117
Hormonal Determinants and Disorders of Peak Bone
Mass in Children*
LESLIE A. SOYKA, WESLEY P. FAIRFIELD, AND ANNE KLIBANSKI
Neuroendocrine Unit and the General Clinical Research Center (W.P.F., A.K.), Massachusetts General
Hospital and Harvard Medical School, Boston, Massachusetts 02114; and Department of Pediatrics
(L.A.S.), University of Massachusetts Medical School, Worcester, Massachusetts 01655
PEAK BONE MASS can be defined as the maximal bonemineral density that is accrued during growth and
development plus subsequent consolidation that continues
during early adulthood (1). The precise age at which peak
bone mineral density is acquired is still unknown and may
be site dependent. It is generally accepted that maximal bone
density is present during the third to fourth decade, but this
assumption is based upon data derived from studies using
densitometry techniques that are less precise than newer
methods. Normative data are derived primarily from cross-
sectional studies of adolescents and young adults, such as
cohorts of the National Health and Nutrition Examination
Survey (NHANES). Differences in absolute density depend
on the various techniques used for assessing bone density [i.e.
single photon absorptiometry, dual energy x-ray absorpti-
ometry (DEXA), quantitative computed tomography (QCT)]
and differences using the same method among different ma-
chines, emphasizing the importance of methodology, includ-
ing the type of machine used when referencing normative
databases. There are also ethnic differences in bone density,
with blacks reported as having higher bone density than
whites. There are gender differences in bone density during
childhood and adolescence due to differences in the timing
of growth and puberty, resulting in females reaching peak
bone mass earlier than males, although bone density values
at peak bone mass are similar between the sexes. An indi-
vidual’s height, bone size, and skeletal age may all impact
bone density values, particularly in growing children and
adolescents. These variables should be considered when as-
sessing the normality of an individual’s bone density, but
unfortunately current reference data do not include infor-
mation on these variables. More recent investigations have
suggested that peak bone mass may be attained as early as
late adolescence in the hip and spine (1). In healthy adoles-
cents, bone mass increases throughout childhood, with max-
imal bone mass accrual occurring in early to midpuberty and
slowing in late puberty (2–5). However, most published
studies are cross-sectional and do not include individuals in
sufficient numbers encompassing the entire age span of in-
terest (i.e. teens to fourth decade) followed prospectively to
definitively determine the age at which peak bone mass is
attained. Longitudinal data from healthy girls demonstrate
that the gain in bone mass is most pronounced between 11–14
yr of age and falls significantly after 16 yr of age and/or 2 yr
after menarche, as shown in Fig. 1 (4, 5). These data suggest
that there is a critical window in time to maximize bone
density in early and midadolescence, and the majority of
bone mass will accumulate by late adolescence. It has been
shown in adult patients that each sd reduction in bone den-
sity is associated with a doubling of fracture risk. In children,
as in adults, fracture rates have also been shown to be higher
in individuals with a lower bone mineral content (6). Because
an individual’s bone density is determined by peak bone
density and the degree of later bone loss, an understanding
of the factors responsible for maximizing peak bone mass is
critical for preventing fractures in later life. In this review, the
factors that influence the attainment of peak bone mass,
particularly hormonal determinants and disorders, will be
considered.
Genetic determinants of peak bone mass
There are important genetic determinants of bone density,
as suggested by studies of twins and families (7–9), and the
specific inherited factors involved are under investigation.
Polymorphisms in the gene encoding the 1,25-dihydroxyvi-
tamin D receptor may in part underlie genetic variation in
bone mass (10–12). Studies examining the relationship be-
tween vitamin D receptor (VDR) polymorphisms and bone
density have provided conflicting results, and a meta-anal-
ysis of studies in adults suggest that the VDR genotype
makes a small contribution to observed bone density (11). In
contrast, in a genetically homogeneous population of chil-
dren, Sainz et al. reported that VDR polymorphisms ac-
counted for a significant (.1 sd) difference in femoral and
vertebral bone density between the homozygous recessive
(aa, bb) and the dominant (AA, BB) genotypes (12). These data
suggest that genotype may be of greater importance in pre-
dicting bone density early in life before age- and gonadal
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steroid-related factors affect bone mass. Studies in adults
have suggested that calcium intake may be related to VDR
genotype and bone density (13, 14). Similarly, in a study of
prepubertal girls, dietary calcium intake correlated with
change in bone density in those with homozygous dominant
and heterozygous (BB and Bb) genotypes, but not in those
subjects with the homozygous recessive (bb) genotype (15).
These data suggest that VDR genotyping may be one factor
determining the variation in bone density in children and
could potentially be helpful in predicting benefits from cal-
cium supplementation. Several other genetic loci that may
play an important role in peak bone mass accrual are under
investigation. A polymorphism in the Sp1 binding site of the
collagen type 1 a1 gene (COLIA1) is one such candidate gene.
This polymorphism is associated with decreased spinal bone
density in prepubertal children with heterozygous (s) and
homozygous recessive genotypes compared with the dom-
inant (S) genotype, similar to findings in adult patients (16).
The insulin-like growth factor I (IGF-I) gene is another im-
portant candidate due to its significant effects as a bone
trophic hormone, although its role in peak bone mass has not
been determined. The important role of estrogen in both male
and female bone maturation and density suggests that es-
trogen receptor gene polymorphisms may also influence
bone density. The XbaI restriction site of the estrogen recep-
tor gene has been found to be related to bone density in
studies of both adolescent boys and premenopausal young
women (17, 18). Therefore, a growing number of candidate
genes have been identified that may be important determi-
nants of peak bone mass. Genetic studies in large populations
with well characterized phenotypes will be critical in assess-
ing the impact of these factors on peak bone mass.
Hormonal determinants of peak bone mass
The presence of osteopenia in patients with abnormal pu-
bertal development demonstrates the critical impact of pu-
bertal hormone changes on normal bone mineral acquisition.
Adult patients with hypogonadotropic hypogonadism com-
monly have osteopenia, resulting from inadequate bone min-
eral accrual during puberty and/or abnormal bone remod-
eling after puberty as shown in Fig. 2 (19). Adult men with
a history of constitutional delay of puberty have been re-
ported to have decreased bone mass (20), although data are
conflicting (21). Androgen receptors are located in growth
plate osteoblasts in males and females and are thought to
mediate the anabolic effects of testosterone in bone (22).
However, estrogen appears to be the more important sex
steroid involved in skeletal maturation and mineralization,
although it is unknown whether estradiol acts directly on
bone or indirectly by stimulating other mediators of bone
growth (2–5, 23, 24). There are reports of rare patients with
aromatase deficiency or estrogen receptor defects resulting
in complete resistance; these subjects have a phenotype that
includes tall stature and normal secondary sexual charac-
teristics. However, these patients have osteoporosis and skel-
etal immaturity in adulthood despite normal androgen levels
(25–27). Treatment of a male patient with aromatase defi-
ciency with estrogen resulted in dramatic improvement in
bone density and completion of skeletal maturation, indi-
cating the critical role of estrogen in skeletal mineralization
and maturation (see Fig. 3) (28). In young women, a high
incidence of metatarsal stress fractures has been reported in
ballet dancers, particularly in those with late age of menarche
and long periods of secondary amenorrhea as shown in Fig.
4 (29). In female adolescents, lower lumbar bone density is
seen in amenorrheic teens compared with those with normal
menses, but the decrease in bone density is generally not
significant when bone density is controlled for body weight
(30–32). These data suggest that nutritional status, including
nutritionally dependent growth factors, and gonadal status
may be independent determinants of bone density. Estrogen
deficiency, particularly in the setting of undernutrition, can
lead to permanent osteopenia. Bachrach et al. found that one
third of females who recover from anorexia nervosa during
adolescence have persistent osteopenia (33). Women with
anorexia nervosa who have disease onset during adolescence
have lower spinal bone density than those with disease onset
in adulthood (34). These data are consistent with the hy-
FIG. 1. Gain in bone mass during ad-
olescence. Yearly increase in spine bone
mineral content (L2-L4) during adoles-
cence in females (V) and males (v). (Re-
printed with permission from The Jour-
nal of Clinical Endocrinology &
Metabolism, 75:1062, 1992. Copyright
© 1992 The Endocrine Society. All
rights reserved.)
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pothesis that there may be a narrow window in time during
adolescence in which maximal bone mass accrues. Prolonged
gonadal steroid deficiency during this time will probably
have a permanent impact on adult bone mass.
Levels of GH and IGF-I increase dramatically during nor-
mal puberty, augmented by increasing levels of sex steroids.
Much of the GH action on bone is mediated through IGF-I.
IGF-I functions in an endocrine and autocrine/paracrine
manner as a bone trophic hormone that positively affects
bone growth and bone turnover by stimulating osteoblasts,
collagen synthesis, and longitudinal bone growth (35–37).
Therefore, in GH-deficient children, bone density and mark-
ers of bone formation are significantly reduced and improve
with recombinant human GH treatment (38). Adult patients
with untreated pubertal GH deficiency have reduced bone
mass compared with treated patients (39). Therefore, GH
deficiency during adolescence may lead to persistent os-
teopenia in adulthood.
Nutritional factors
Body weight is a major determinant of bone density in chil-
dren and adolescents. Studies in healthy normal weight and
obese children and adolescents demonstrate that lean body
mass correlates with total and lumbar bone mineral content
(40). Adolescents with nutritional disorders are often also hy-
pogonadal, making it difficult to determine the impact of these
individual factors on bone density. In adolescents with nutri-
tional disorders such as anorexia nervosa, the relationship be-
tween body mass and bone density is not present (41, 42),
suggesting that multiple factors probably interact. In adolescent
anorexia nervosa patients there is an imbalance in bone me-
tabolism, with low bone formation uncoupled with resorption,
in association with low bone density (42). IGF-I levels are re-
duced in these patients, probably due to combined effects of GH
resistance (43) in addition to reduced liver IGF-I gene expres-
sion with undernutrition (37). Low bone formation in adoles-
FIG. 2. Reduced bone density in idiopathic hypogonadotropic hypogonadism. Spinal trabecular bone density compared with age in 23 men with
idiopathic hypogonadotropic hypogonadism. v, Patients with fused epiphyses; V, patients with open epiphyses. The solid line indicates the mean
spinal bone density in normal adult men, whereas the dotted line indicates 61 SD from the mean. The stippled bar indicates the fracture
threshold. (Reprinted with permission from Annals of Internal Medicine, 106:358, 1987. Copyright © 1987 American College of Physicians.)
FIG. 3. Increased bone density in a man with aromatase deficiency
during estrogen therapy. The percentage increase from baseline val-
ues is shown for the lumbar spine. Specific measurements were made
at baseline, 12, 30, and 36 months. (Reprinted with permission from
New England Journal of Medicine, 339:602, 1998. Copyright © 1998
Massachusetts Medical Society. All rights reserved.)
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cent girls with anorexia nervosa has been found to correlate
strongly with levels of IGF-I (42).
Calcium intake has been shown to correlate with bone
density in healthy children and adolescents. In a group of 151
healthy girls and boys, 7–15 yr old, Ruiz et al. reported that
dietary calcium intake was the most significant determinant
of spinal bone density, and that the majority of children with
low spinal and femoral neck bone density had low dietary
calcium intake (44). Other studies have found a small or
negligible effect of dietary calcium on regional bone density
(3, 45). Dietary calcium requirements increase substantially
around the time of peak growth velocity and bone mineral
accrual (46). Dietary calcium supplementation has been
shown to improve bone density, but it is unclear whether the
effect is sustained once supplementation is stopped. A long-
term (3-yr), double blind, placebo-controlled trial of calcium
supplementation in identical twin pairs, 6–14 yr old, showed
that there was a significant effect of supplementation on
radial and spinal bone density in prepubertal subjects, but
not in pubertal subjects (47). A shorter term (18-month) trial
did find a positive effect of increasing calcium intake from
below to above the recommended daily allowance of calcium
on bone density of the spine, but not of the peripheral sites
in adolescent girls (48). Whether calcium or other micronu-
trient supplementation can lead to improvement in peak
bone mass remains unknown. Little is known regarding the
definitive role of these factors in younger patients. There is
probably an age-specific effect of many of these factors in the
developing skeleton; therefore, it is important to define the
impact of these variables on the development of bone density
during childhood and adolescence.
Other determinants of peak bone mass
Physical activity, particularly weight-bearing exercise, is
known to have a positive effect on bone density in children and
adolescents (3, 49). A study of 45 prepubertal gymnasts showed
increased bone density compared with controls, and the dura-
tion of training correlated with bone density. Furthermore, the
gymnasts had a 30–85% greater increase in areal bone density
in the spine and legs over 12 months than bone age-matched
prepubertal controls. In addition, a group of retired young adult
female gymnasts had higher bone density at all sites (z-score,
0.5–1.5) compared with age-, height-, and weight-matched con-
trols, suggesting a persistent beneficial effect of prior physical
activity (49). However, excessive exercise during adolescence
may lead to delayed puberty, amenorrhea, and low bone den-
sity (50). Therefore, the timing, intensity, and duration of the
physical activity may determine whether it will have a positive
or negative effect on bone density.
FIG. 4. Relationship between age at
menarche and the percentage of young
dancers (n 5 75) with fractures and
stress fractures. (Reprinted with per-
mission from New England Journal of
Medicine, 314:1351, 1986. Copyright ©
1986 Massachusetts Medical Society.
All rights reserved.)
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Disorders resulting in low peak bone mass
Turner syndrome. Low bone density is seen in children, ad-
olescents, and adult patients with Turner syndrome, and an
increased incidence of wrist fractures has been reported.
Although abnormalities in gonadal steroids and GH secre-
tion probably contribute to the osteopenia in this disorder,
abnormalities have also been reported in prepubertal girls,
suggesting an intrinsic bone defect. Bone metabolism studies
using surrogate markers and histomorphometric analysis in
children and adolescents with this disorder are consistent
with a state of low bone turnover. Deficits in bone density
have been shown in both cortical (radius) and trabecular
(spine) bone. Data on bone density reduction at the lumbar
spine vary depending on whether values are in reference to
chronological or skeletal age, body mass index, or height and
whether patients have received GH or estrogen treatment
(51). In untreated young girls, 4–13 yr old, the largest study,
in 78 patients, demonstrated normal spinal bone density
when they were matched for bone age and height with pre-
pubertal controls, and normal radial bone density when they
were matched for height despite a significantly increased rate
of wrist fractures (52). The investigators suggest that the
increase in observed wrist fracture rate may be due to either
an intrinsic structural defect or an increased rate of falling in
these girls. Other studies have shown reduced bone density
in these patients, but did not account for the variables
(height, bone age, and body size) that may impact on bone
density measurements. Of these factors, accounting for
height is particularly important in this patient group due to
their significant short stature and associated reduced bone
size. Because the most commonly used method of bone den-
sity measurement, DEXA, provides an areal density mea-
surement rather than a true volumetric density, individuals
with bigger bones will have a greater reported bone density
value. Methods to account for bone size when assessing bone
density include the use of QCT or calculated volumetric bone
density measurements (45) and are particularly useful in
these patients.
Bone density and fracture risk in Turner patients are de-
pendent upon treatment with GH and/or estrogen. In young
Turner patients treated with GH, lumbar bone density or
bone mineral apparent density is normal compared with that
in healthy girls matched for bone age, height, and pubertal
stage (53). In small, short-term studies, bone density in-
creases with estrogen treatment (54), but there are no long
term studies to determine whether estrogen therapy im-
proves peak bone mass and, if so, what the timing and dosing
requirements of estrogen administration are. The importance
of estrogen deficiency is suggested by several studies in adult
women with delayed exposure to estrogen. Radial bone den-
sity has been negatively correlated with age at initiation of
estrogen replacement in adult Turner women (age, 20–50 yr)
who did not enter puberty spontaneously (55). A significant
reduction in spinal bone density has been shown in 40
women with Turner syndrome compared with healthy
women of similar height and weight. The women with pri-
mary amenorrhea, indicating a longer duration of estrogen
deficiency, had a significantly higher rate of fractures com-
pared with women who had some spontaneous menses.
Approximately 50% of the women with Turner syndrome
had sustained fractures at typical postmenopausal osteopo-
rotic sites, including the vertebrae, femoral neck, and wrist
(56). Adult women with Turner syndrome in whom estrogen
therapy was delayed or insufficient had significantly lower
lumbar bone density than women who had received estrogen
replacement beginning at 16–18 yr of age. Both groups had
significantly reduced bone density compared with normal
women, but limitations of the study include lack of infor-
mation on both height and bone age in the untreated patients
(57). Overall, these data suggest that a prolonged duration of
estrogen deficiency, particularly during adolescence, prob-
ably contributes to low bone density in women with Turner
syndrome.
Klinefelter syndrome. It is not known whether the chromo-
somal defect in Klinefelter syndrome (XXY) has an effect on
bone density independent of gonadal steroid deficiency.
There are data to suggest, however, that the characteristic
long bone abnormality, with increased lower body segment,
is present before puberty and therefore is probably attrib-
utable to the underlying genetic defect rather than androgen
deficiency (58). Young hypogonadal men with Klinefelter
syndrome are at risk for low bone density, although bone
density measurements in these patients have not been widely
published. Horowitz et al. (59) reported significantly de-
creased forearm bone density in association with low bone
formation and high resorption assessed by bone turnover
markers in 22 adult men (19–68 yr old) with Klinefelter
syndrome. There was no significant difference in forearm
bone density between testosterone-treated or untreated pa-
tients; however, there was a significant relationship between
bone density and serum testosterone levels. Sites composed
of primarily trabecular bone, which are generally more af-
fected in hypogonadal states, have not been examined in
these studies. Therefore, although early diagnosis and treat-
ment of androgen deficiency is recommended, site-specific
data regarding testosterone administration on bone density
are lacking.
Gonadal steroid insufficiency. Apart from known genetic syn-
dromes, permanent or transient estrogen and testosterone
deficiency during adolescence due to a number of causes
(Table 1) can lead to reduced bone mass. Young adults with
hypogonadotropic hypogonadism have both reduced corti-
cal and trabecular bone density. Finkelstein et al. found that
in 23 such young adult men, 70% had a radial bone density
less than 2 sd below the normal mean, and 35% had spinal
bone density below the fracture threshold (19). Patients had
a similar reduction in bone density regardless of whether
they had attained epiphyseal fusion, suggesting abnormal
pubertal bone mineral accretion rather than accelerated bone
loss alone. Treatment of patients with hypogonadotropic
hypogonadism by maintenance of normal adult levels of
testosterone resulted in an improvement in bone density.
Patients with immature epiphyses had a greater response to
treatment than those with mature epiphyses, but neither
group attained normalization of bone density after an aver-
age of 2 yr (60).
Estrogen deficiency in female adolescents is associated
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with reduced bone density. There are multiple possible
causes of estrogen deficiency in female adolescents. Hypo-
thalamic amenorrhea due to excessive exercise or stress is the
most common cause in otherwise healthy adolescents, par-
ticularly athletes. Although weight-bearing activities during
adolescence can have positive effects on increasing bone
density, excess exercise can lead to low weight and amen-
orrhea. As estrogen deficiency and low weight often occur
together, their independent effects on bone density are dif-
ficult to determine. Several investigators have reported that
teenage and adult amenorrheic patients have reduced bone
density compared with eumenorrheic controls. Warren et al.
found that among a large group of professional ballet danc-
ers, 13–29 yr old, the age at menarche highly correlated with
the occurrence of stress fractures, and those with stress frac-
tures had a significantly later age of menarche than those
without fractures (31). However, when bone density mea-
surements were controlled for weight, much of the difference
between amenorrheic and eumenorrheic subjects became in-
significant (30–32). In the young ballet dancers reported by
Warren et al., lumbar spine bone density was not significantly
different between age- and weight-matched amenorrheic
and eumenorrheic dancers when controlled for weight; how-
ever, metatarsal bone density remained significantly lower in
the amenorrheic group. Therefore, nutritional status may
mediate the site-specific effects of estrogen deficiency on
bone density. Estrogen/progesterone treatment has been
shown in a prospective study of 24 young women runners
(age, 14–28 yr) to significantly improve spinal and total bone
density compared with that in medroxyprogesterone- and
placebo-treated subjects (61). The effects of treatment with
hormone replacement to improve bone formation in adoles-
cent girls with estrogen deficiency has not been evaluated;
therefore, it remains unknown what dose, timing, and du-
ration of therapy may be beneficial.
A delayed timing of puberty may be an independent pre-
disposing factor for reduced peak bone mass. Male patients
with constitutional delay of growth and pubertal maturation
have been reported to have significantly reduced bone mass
during adulthood. Lumbar, femoral neck, and radial bone
density has been found to be 2 sd or greater below the normal
mean in one third of young adult men with a history of
delayed puberty who were not given androgen treatment
during adolescence (20). Significant differences in regional
bone density were present even when bone size was ac-
counted for with calculated volumetric bone density (62).
Other investigators found a similar reduction in areal bone
density in young adult men with a history of constitutional
delay. However, there was no difference in calculated volu-
metric bone density between patients and controls, and there
were no differences among those treated with testosterone,
the nonaromatizable androgen oxandrolone, or untreated
patients (21). Possible reasons for the discrepancy between
these data include the inability to adequately account for
bone size with calculated methods from DEXA measure-
ments and the inclusion of patients with various etiologies
and duration of abnormal growth and development. A fur-
ther prospective study of this patient group throughout ad-
olescence until peak bone mass is attained is needed to de-
termine whether treatment with androgens in adolescent
boys with constitutionally delayed puberty is required to
achieve normal bone density. In female patients, data sim-
ilarly suggest that a delay in the normal timing of pubertal
development results in reduced bone mass. An increased
fracture rate has been reported in young women with a
history of delayed menarche (29, 31). Women with anorexia
who had onset of the disorder during the teenage years have
lower bone density than those in whom the disorder devel-
oped in adulthood (34) and, therefore, after the development
of peak bone mass. However, it is not known whether es-
trogen deficiency alone or deficiency of other gonadal ste-
roids (i.e. testosterone or progesterone) or nutritional vari-
ables is most important during development. Furthermore,
the timing, dosage, and duration of estrogen therapy needed
to maximize peak bone mass are unknown.
Other endocrine disorders
GH deficiency. Untreated GH deficiency during childhood
and adolescence often leads to reduced peak bone mass.
Adults with untreated pubertal GH deficiency have reduced
bone density at the lumbar spine, femoral neck, and Ward’s
triangle compared with treated patients and normal controls
(39). Kaufman et al. studied 30 adult men with childhood-
onset GH deficiency and demonstrated a reduction of 20–
39% in cortical bone density (forearm) and 9–19% in trabec-
TABLE. 1. Disorders resulting in reduced peak bone mass
Genetic syndromes (multifactorial)
Turner syndrome
Klinefelter syndrome
Hypogonadism during adolescence
Hypogonadotropic
Permanent, i.e. Kallman’s syndrome, idiopathic
Delayed, i.e. constitutional delay, anorexia nervosa,
hypothalamic amenorrhea
Hypergonadotropic
Gonadal dysgenesis
Gonadal failure, i.e. autoimmune, chemotherapy/radiation
exposure
Aromatase deficiency
Estrogen receptor defect
Other endocrine disorders
GH deficiency
Cushing’s disease
Hyperthyoidism
Diabetes mellitus
Rickets
Nutritional
Malnutrition
Chronic dietary calcium/vitamin D deficiency
Chronic diseases of childhood and adolescence (multifactorial)
Anorexia nervosa
Inflammatory bowel diseases
Cancer
Cystic fibrosis
Rheumatologic disorders
Osteopathies
Glucocorticoid-induced osteopenia
Osteogenesis imperfecta
Idiopathic juvenile osteoporosis
Neurogenic osteopenia
Metabolic diseases
Homocystinuria
Lysinuric protein intolerance
Menke’s kinky hair syndrome
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ular bone density (spine) (63). In a larger study of 70 adult
men with childhood-onset GH deficiency, one third of pa-
tients had lumbar bone density 2 sd or more below the
normal mean (64). Low bone density measurements may
reflect reduced height and bone size in these patients. Pa-
tients in whom volumetric bone density is measured by QCT
or estimated by calculated methods from DEXA measure-
ments to correct for bone size, however, also have been
shown to have reduced spinal bone density compared with
age- and sex-matched reference data (65, 66). Although a
subset of patients studied had received prior treatment with
GH, the adequacy of treatment dosage and timing has not
been established. In children and adolescents with GH de-
ficiency, bone density and markers of bone formation are
significantly reduced and improve with recombinant GH
treatment in short-term studies (37, 67, 68). A 2-yr study of
38 treated GH-deficient children, 4–16.9 yr old, demon-
strated increased lumbar bone density by DEXA after 6
months of treatment but no significant change in calculated
volumetric bone density until after 2 yr of treatment. These
data indicate that early changes in bone density measure-
ments may reflect changes in bone size, but prolonged treat-
ment results in improvement in net bone formation (68).
Longitudinal data in 32 GH-deficient children, 7.2–16.3 yr
old, treated with GH for an average of 4 yr demonstrated a
significant improvement in radial and lumbar bone density
with therapy (Fig. 5) (69). The greatest improvement was
observed with the longest treatment duration, and in this
group, z-scores approached mean reference values. A group
of 11 patients, 16–18.7 yr old, who had reached final height
had significantly reduced lumbar bone density compared
with short normal controls. Possible reasons for this include
the interrupted and low dose GH treatment the patients
received during the era of pituitary-derived GH. GH treat-
ment appears to have a more pronounced effect on bone
density in patients with childhood-onset GH deficiency than
in those with adult-onset GH deficiency (70). Young adult
men with childhood-onset GH deficiency who resumed GH
treatment for 3–5 yr during adulthood demonstrated a sig-
nificant (9.6–16.2%) improvement in lumbar, femoral neck,
and trochanter bone density, with the most significant effects
observed in those with lower baseline bone density z-scores
(71). These data suggest that GH treatment leads to improved
bone density, which is a function of the dose and duration
of treatment, and that patients may require prolonged GH
treatment beyond the time of growth to improve peak bone
mass.
Cushing’s disease. Patients with Cushing’s disease may have
reduced bone mass due to the direct effect of hypercortisol-
emia on bone and the secondary hypogonadal state. The
presence of osteopenia and vertebral collapse in a prepu-
bertal child with Cushing’s disease (72) suggests that cortisol
excess is causative. Due to the rarity of this disorder in
children, limited data on bone density are available. In the
two largest published series of pediatric patients with Cush-
ing’s disease (n 5 101 patients total, 4–20 yr old), bone
density measurements were performed at diagnosis in only
three patients, and only one patient had a fracture at diag-
nosis (73, 74). The patients in whom densitometry was per-
formed had severe osteopenia (z-score 5 23.9 to 27.0),
which improved, but remained reduced, after treatment (73).
Leong and colleagues described marked lumbar osteopenia
(23.2 sd) in a 15-yr-old girl with long-standing Cushing’s
disease during adolescence. Serum osteocalcin was mark-
edly reduced pretreatment, suggesting low bone formation.
After more than 2 yr of follow-up, bone density increased
considerably, but remained reduced compared with that in
her normal twin (75). These data suggest that reduced peak
bone mass is a complication of Cushing’s syndrome in child-
hood and adolescence, and relates to the duration of in-
creased cortisol secretion. Specific hormonal or other thera-
peutic strategies to improve bone mass in this patient group
have not been investigated.
Hyperthyroidism. Reduced bone mineral density in adult pa-
tients with untreated hyperthyroidism is common; however,
data on the effects of hyperthyroidism on peak bone mass are
limited. A study of 13 girls with hyperthyroidism, 5–14.9 yr
old, demonstrated significantly reduced whole body and
FIG. 5. Increase in bone density in children with GH deficiency receiving rhGH treatment. Mean radial BMD Z-score (left) and mean lumbar
BMDarea Z-score (right) corrected for bone age in children with GH deficiency receiving rhGH treatment. Parentheses enclose the number of
examined children. o, P , 0.001 vs. reference values; *, P , 0.01; **, P , 0.001 vs. 0. (Reprinted with permission from The Journal of Clinical
Endocrinology & Metabolism, 81:3080, 1996. Copyright © 1996 The Endocrine Society. All rights reserved.)
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spinal bone density at diagnosis compared with healthy girls
matched for age and body size. The low bone density in
untreated hyperthyroid girls occurred in association with
elevated bone resorption as assessed by urinary N-telopep-
tide (76). However, bone formation was not assessed. Thy-
roid hormone levels correlated negatively with bone density
and positively with N-telopeptide in these patients. Both
bone density and bone resorption were no longer signifi-
cantly different from control values at 12 and 24 months of
follow-up in patients receiving successful medical treatment.
These data suggest that untreated hyperthyroidism nega-
tively effects bone metabolism and bone density in youths,
but that the effects can be corrected with treatment and are
therefore unlikely to affect peak bone mass in adequately
treated patients.
Type 1 diabetes mellitus. There are conflicting data regarding
whether reduced bone density is a complication of type 1
diabetes mellitus. The majority of studies in adults demon-
strate osteopenia of cortical and trabecular sites, which is
generally correlated with the level of blood glucose control
and duration of diabetes, and the incidence is increased in
patients with other chronic complications of diabetes (77–79).
Although an increased fracture risk has not been found in
this patient group, increased calcaneal fractures have been
reported in patients with long-term vascular complications
and in those receiving steroid treatment (80, 81). Osteopenia
appears to be minimally progressive in adulthood (77, 82),
suggesting that the low bone density seen in adult patients
may result from a reduction in peak bone mass. Studies in
children and adolescents with a short duration of diabetes,
however, have shown no differences in spinal and peripheral
bone density assessed by DEXA between patients and age-
and sex-matched controls (83–85). Using QCT, which allows
selective measurement of trabecular and cortical bone, the
largest study (86) of 48 diabetic children and adolescents,
5.2–19.6 yr old, found a small significant decrease (3.5%) in
cortical bone density and no difference in trabecular bone
density in patients compared with controls matched for age,
sex, skeletal and pubertal maturation, and anthropometric
measurements. The reduction in cortical bone density did not
correlate with the duration of diabetes or the level of control,
as assessed by glycosylated hemoglobin. In contrast, Lettgen
et al. (87) studied a smaller group (n 5 21) of diabetic children
and adolescents, 6.2–19.9 yr old, of variable disease duration
(0.8–18. yr) using forearm QCT and demonstrated signifi-
cantly decreased trabecular bone density (218.9%) and a
smaller (25.1%), nonsignificant decrease in cortical bone
density compared with age-, pubertal stage-, and sex-
matched controls. The duration of diabetes and glycosylated
hemoglobin was significantly inversely correlated with tra-
becular bone density in these patients. Therefore, the ma-
jority of data demonstrate a small or negligible reduction in
bone density in children and adolescents with diabetes mel-
litus; however, data are limited to cross-sectional studies.
Longitudinal data on bone mineral accretion during child-
hood and adolescence are needed to identify those patients
who may be at risk for low peak bone mass. Osteopenia may
develop over the long term, with patients in poor control and
with other diabetic complications at highest risk.
Glucocorticoid therapy. Osteopenia and growth retardation are
common complications of glucocorticoid therapy in pediatric
patients. The rate of bone loss is related to glucocorticoid
dose, but osteopenia occurs in children receiving less than
0.16 mg prednisone/kgzday (88). Loss of bone occurs most
rapidly in the first 6 months of glucocorticoid therapy (89)
predominantly in trabecular bone (90–92). Glucocorticoid-
induced osteopenia and failure to achieve peak bone mass
are thought to result from multiple factors, including direct
effects of glucocorticoids on bone, impaired calcium absorp-
tion, abnormal renal calcium handling, reduced gonadal ste-
roid secretion, and changes in the GH/IGF-I axis (89).
Bone undergoes constant remodeling, and any factor caus-
ing bone resorption to exceed bone formation will result in
bone loss. Several lines of evidence suggest that glucocorti-
coids impair bone formation (93–95). Glucocorticoid admin-
istration may also increase bone resorption, although the
evidence of a direct effect of glucocorticoids on bone resorp-
tion is less extensive (95, 96).
Glucocorticoid effects on mineral metabolism represent a
partial explanation for glucocorticoid-induced alterations in
bone formation and resorption. Glucocorticoids impair cal-
cium absorption in the duodenum (97) and result in second-
ary hyperparathyroidism, stimulating osteoclastic activity
and bone resorption (98). Glucocorticoid-induced alterations
in vitamin D metabolism are also postulated, but are con-
troversial (99, 100).
Glucocorticoids may impair the attainment of peak bone
mass through alterations in gonadal function at the level of
the pituitary and through direct effects on the gonads (101–
103). Although hypogonadism may be a contributing factor
to glucocorticoid-induced osteoporosis in adolescents, bone
loss still occurs in the presence of clinically normal gonadal
function (89).
Glucocorticoids may also impair the attainment of peak
bone mass via effects on the GH/IGF-I axis. High dose,
long-term glucocorticoid therapy markedly attenuates GH
secretion (104). The impact of short-term glucocorticoid ex-
posure on skeletal development in children varies from
study to study depending upon the dose and timing of glu-
cocorticoid therapy and the method used to assess GH se-
cretion. However, regardless of the effects on circulating
IGF-I, IGF-I activity appears to fall within hours of glucocor-
ticoid administration in children whose peripheral IGF-I lev-
els remain unchanged (105).
Bone loss in children receiving glucocorticoids is dose
related, and therefore it is prudent to prescribe the lowest
effective dose. Although preserving the normal function of
the hypothalamic-pituitary-adrenal axis, alternate-day glu-
cocorticoid regimens do not prevent bone loss (106). There-
fore, children and adolescents receiving glucocorticoid ther-
apy may be at risk for effects on attainment of peak bone
mass and bone loss. Specific interventions to protect bone
mass in glucocorticoid-treated children have not been as-
sessed, although maintaining normal calcium and vitamin D
intake is recommended. In addition, postpubertal adoles-
cents receiving chronic glucocorticoid therapy should be
monitored for development of hypogonadism.
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Nutritional disorders. Multiple disorders resulting in deficient
caloric and micronutrient (calcium and vitamin D) intake
during childhood may affect peak bone mass. Specific nu-
tritional disorders associated with reduced bone density in-
clude inflammatory bowel disease (IBD), celiac disease, and
anorexia nervosa.
Inflammatory bowel disease. Both types of IBD are associated
with an increased prevalence of osteopenia (107), although
among patients with IBD, those with Crohn’s disease have
been noted to have a higher risk of osteopenia than those
with ulcerative colitis (108). Semeao et al. (109) found that of
119 children and young adults with Crohn’s disease, 70% of
patients’ had bone mineral density z-scores at least 1 sd
below the normal mean, and 32% had scores at least 2 sd
below the normal mean. Nutritional factors such as the use
of hyperalimentation, vitamin D deficiency, and calcium
malabsorption may contribute to bone loss in adolescents
with IBD (110). In the above-mentioned cross-sectional study
of 119 children and young adults with Crohn’s disease, low
bone density was associated with the use of nasogastric tube
feeds and total parenteral nutrition independent of glucocor-
ticoid use (109). Although alterations in vitamin D metabo-
lism as well as calcium/mineral metabolism are thought to
contribute to bone loss in IBD, this has not been demon-
strated in some clinical studies (111).
The reduction in bone density in children with IBD is
probably multifactorial. In addition to nutritional factors,
other complicating factors include poor linear growth, de-
layed puberty, and therapies used to treat IBD. Although
several studies have found glucocorticoid treatment to have
the strongest correlation with bone density in these patients
(112, 113), IBD is a risk factor for accelerated bone loss in-
dependent of the use of glucocorticoids (114, 115). In addition
to glucocorticoid therapy, accelerated bone loss may occur
due to the use of cyclosporin and 6-mercaptopurine (109,
110). Bone loss associated with IBD may also result from the
production of inflammatory cytokines (110). Cytokines such
as interleukin-1, interleukin-6, and tumor necrosis factor,
released during the inflammatory state, are thought to recruit
and activate osteoclasts, perhaps contributing to bone loss
and failure to attain peak bone mass (116).
Therapy for the prevention of bone loss in children with
IBD is limited. There are no studies directly comparing cal-
citonin with vitamin D and calcium supplementation in this
population. Bisphosphonates have been shown to prevent
glucocorticoid-induced osteoporosis in a multicenter study
of 477 corticosteroid treated adults (24 with IBD) (117) and
in a small series of corticosteroid-treated children (118).
However, the long-term impact of bisphosphonate therapy
upon skeletal development in children is unknown, and the
use of bisphosphonates in children remains experimental at
the present time (119).
Celiac disease. Children with the common pediatric enterop-
athy celiac disease, in which nutrient absorption is impaired,
are also at risk for reduced bone density. Mora et al. dem-
onstrated significantly reduced lumbar and total bone den-
sity at diagnosis of celiac disease in 44 patients, 2.6–20.4 yr
old, after controlling for anthropometric measurements
(120). Follow-up studies of these patients on a gluten-free
diet demonstrated normalization of bone density.
Anorexia nervosa. Anorexia nervosa is another important nu-
tritional cause of osteopenia commonly seen in adolescent
girls, with spinal (trabecular) bone density most commonly
affected. Lumbar bone density is reduced more than 1 sd
below the normal mean in nearly half of height- and bone
age-matched adolescent girls (42) and correlates with the
duration of anorexia (41, 42). Adult women with anorexia
nervosa who had onset of the disorder during adolescence
have more severe osteopenia than those who developed the
disorder during adulthood (34), indicating that abnormal
bone mineral accrual occurs in adolescent patients. Surrogate
markers of bone turnover demonstrate reduced bone forma-
tion uncoupled to bone resorption in adolescent girls with
anorexia nervosa (Fig. 6), with the majority of the variation
in bone formation due to the nutritionally dependent bone
trophic hormone IGF-I (42). Therefore, nutritional status, in
addition to gonadal steroid deficiency, is an important factor
in the development of osteopenia in adolescents with an-
orexia nervosa. Improvement in bone density is seen with
weight recovery before resumption of menses, suggesting
the importance of nutritional status; however, significant
osteopenia may persist (33). Potential negative effects on
bone density from excessive exercise, increased cortisol se-
FIG. 6. Reduced bone formation uncoupled from bone resorption in adolescent girls with anorexia nervosa. Comparison of bone turnover
markers in subjects with anorexia nervosa (AN; n 5 11) and controls (n 5 15). OC, Osteocalcin; BSAP, bone-specific alkaline phosphatase; DPD,
deoxypyridinoline. *, P 5 0.02 for AN subjects vs. bone age-matched controls. (Reprinted with permission from The Journal of Clinical
Endocrinology & Metabolism, 84:4494, 1999. Copyright © 1999 The Endocrine Society. All rights reserved.)
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cretion, and reduced calcium and vitamin D intake in these
patients have not been proven. These data emphasize the
importance of early diagnosis and treatment of underlying
nutritional disorders in childhood to acquire normal peak
bone mass.
Chronic diseases of childhood and adolescence
Cancer. Children and adolescents who undergo treatment for
malignancy are at risk for poor bone mineral accrual due to
the combined effects of the disease and treatment with glu-
cocorticoids, chemotherapeutic agents, and cranial irradia-
tion. The endocrine effects of treatment that contribute to
osteopenia include GH deficiency and hypogonadism. In
addition, these patients may have poor nutritional intake,
reduced vitamin D levels, and low levels of physical activity,
which may impact bone development. In a study of 28 chil-
dren with leukemia or solid tumors, 2.9–16 yr old, calculated
volumetric femoral and lumbar bone density was normal at
diagnosis, but femoral bone density decreased by 11.3% over
1 yr. A small decrease (2.4%) in lumbar bone density in
patients older than 7 yr was seen, but was not significant
(121). Bone markers demonstrated reduced bone formation
at diagnosis, with bone formation normalizing and resorp-
tion increasing with treatment, suggesting that the disease
and its treatment may have differing effects on bone turn-
over. Patients with acute lymphoblastic leukemia (ALL) ap-
pear to be at a higher risk for osteopenia than those with other
malignancies. Warner et al. found that in 35 child and ado-
lescent survivors of ALL (7–19 yr of age, minimum of 18
months after completion of therapy), the percentage of pre-
dicted bone mineral content was reduced at the hip com-
pared with 20 age-matched survivors of other malignancies
and 31 sibling controls. In addition, although there was an
improvement in the percentage of predicted bone mineral
content at the spine with increasing duration of time off
therapy, there was significantly less improvement in the ALL
group compared with the group with other malignancies
(122). In some studies, regional bone density has been cor-
related with previous exposure to specific chemotherapeutic
agents as well as cumulative dosing (121, 122).
Among the long-term consequences of treatment of child-
hood malignancy, GH deficiency due to hypothalamic-pitu-
itary damage from intracranial radiation therapy is common.
In a study of 21 young adults who were treated for intra-
cranial malignancy during childhood, all developed GH de-
ficiency by the end of puberty. Those who did not receive GH
treatment were osteopenic at the femoral neck, lumbar spine,
and Ward’s triangle compared with the GH-treated patients
(123). However, other published data indicate that osteope-
nia may be present despite GH replacement in childhood
brain tumor survivors (124). Therefore, the etiology of os-
teopenia in this patient group is probably multifactorial.
What specific interventions may improve bone density in
this patient population remain unknown; however, maxi-
mizing nutritional status, including calcium and vitamin D
intake; minimizing immobilization; and replacing hormonal
deficiencies when present should be part of the standard
treatment.
Cystic fibrosis. Osteopenia is a common complication of cystic
fibrosis in children and adults, which will probably signif-
icantly impact the quality of life in these patients as they
continue to live longer. In adults, fracture rates have been
reported to be 2 times greater in young women and men with
cystic fibrosis than in the general population, with a partic-
ularly high risk for rib and vertebral compression fractures
(10- to 100-fold risk) (125). Analysis of surrogate markers of
bone turnover demonstrates an imbalance, with low bone
formation and increased resorption in pubertal and young
adult patients (126). Both poor bone mineral accrual and
accelerated bone loss are implicated in the pathogenesis of
osteopenia in these patients (126–128); however, few longi-
tudinal data are available. One longitudinal study of 41
youths and adults with cystic fibrosis (9–50 yr of age) eval-
uated interval change in bone density over an average fol-
low-up period of 17 months. Although spinal hip and whole
body bone density were reduced at baseline in all subjects,
continued decreases were seen only in subjects less than 18
yr old. These data are consistent with poor bone mineral
accretion in young patients with cystic fibrosis (128). The
cause of the low bone density in this population appears to
be multifactorial, being variably correlated with low body
mass, vitamin D insufficiency, glucocorticoid therapy, se-
verity of illness, decreased physical activity, and hypogo-
nadism (127, 129–132). There are no published therapeutic
trials of treatment of low bone density in cystic fibrosis;
however, one randomized controlled study in adults re-
ported severe bone pain after iv pamidronate therapy, pos-
sibly related to increased production of inflammatory cyto-
kines (133, 134).
Rheumatological disorders. Rheumatological disorders such as
juvenile rheumatoid arthritis (JRA) have been associated
with growth retardation (135) and low bone mineral density
even in the absence of therapy with glucocorticoids (136–
138). Osteoporosis associated with pathological long bone
fractures as well as vertebral compression fractures have
been reported in 20% of children with JRA (139). In one
cross-sectional study, 30% of children with mild to moderate
JRA had low total body bone mineral density (137). JRA
appears to be associated with a low bone turnover state, as
determined by reductions in both markers of bone formation
as well as markers of bone resorption (138). The etiology of
bone loss in JRA is probably multifactorial, with possible
contributions from inflammatory cytokine production, di-
minished physical activity, alterations in nutritional factors,
and the use of immunomodulatory agents (137, 138).
Other systemic rheumatological diseases, such as systemic
lupus erythematosus and juvenile dermatomyositis, have
been associated with reductions in bone mineral density.
However, given the widespread therapeutic use of cortico-
steroids, it is difficult to demonstrate independent effects of
these diseases on bone density. One prospective study of 113
children with chronic rheumatological diseases (including
systemic lupus erythematosus, juvenile dermatomyositis,
and JRA) demonstrated a reduction in osteocalcin, which
was greatest in children with active disease before any treat-
ment with corticosteroids (140). The precise mechanisms by
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which these chronic inflammatory diseases result in osteope-
nia remain unclear and are likely to be multifactorial.
Conclusions
Normal bone mineral accretion during childhood and ad-
olescence is a complex process involving genetic determi-
nants, gonadal steroids, GH/IGF-I effects, and nutritional
and other environmental factors. Assessing the normality of
bone density measurements in childhood by the current
methods is complicated by the lack of normative data in large
populations of children who are well characterized in terms
of anthropometric measurements and pubertal and skeletal
maturation. Nevertheless, data identify numerous hormonal
disorders that predispose young patients to reduced peak
bone mass and thereby increased risk of life-long osteopo-
rosis. These data support the importance of the awareness of
risk factors for osteopenia in adolescents at risk and of cor-
recting hormonal and nutritional disorders when present.
The cause of many osteopenic disorders in childhood is mul-
tifactorial; therefore, there is a need for further elucidating
the pathogenesis of poor bone mineral development. Future
research is clearly needed in this area to develop treatment
strategies to preserve maximal bone mass in patients at the
highest risk for reduced peak bone mass.
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